Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Nashville, AR
NPI: 1346227048Primary Practice Location
HOWARD MEMORIAL HOSPITAL
130 Medical Cir, Nashville, AR
Primary Employer
Zangmeister Cancer Center
zangcenter.com
HQ Phone
Get M.D. Roy's Phone Numberphone_androidMobile
Get M.D. Roy's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardAR State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 682 | 1,853 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 386 | 794 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 375 | 880 |
| 4 | 36415Insertion of needle into vein for collection of blood sample | 326 | 503 |
| 5 | 96372Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 197 | 643 |
Authors: Aapro, Matti S, Schmoll, Hans J, Jahn, Franziska, Carides, Alexandra D, Webb, R Timothy
Journal: Cancer Treat Rev
Publication Date: 2012-10-11
A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Authors: Barrett Childs
Publication Date: 2013-03-13
Authors: Lowell Hart, Rajesh Malik, Steven Schuster, Steven Schuster, Robert Jotte
Journal: Cancer Chemother Pharmacol
Publication Date: 2021-02-17
Lead Sponsor: ImmunityBio, Inc.
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab, DRUG: N-803 + Pembrolizumab, DRUG: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab, DRUG: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, DRUG: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab, DRUG: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Lead Sponsor: G1 Therapeutics, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: Topotecan, DRUG: Trilaciclib
Lead Sponsor: G1 Therapeutics, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: Carboplatin, DRUG: Etoposide, DRUG: Trilaciclib
